Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

- PMLiVE

Sanofi launches Diversity, Equity & Inclusion Board

The Board is the first of its kind in the pharma industry to have outside advisors

- PMLiVE

ICR scientists create AI test to predict cancer drug combinations

The technique uses artificial intelligence (AI) to analyse large-scale protein data from tumour samples

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis

The results were announced at the American Academy of Dermatology 2022 Annual Meeting

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

Consumer-driven Healthcare in the Digital Age

Dr. Gil Blander, Co-founder & Chief Scientific Officer at InsideTracker, explores consumer-driven healthcare, the use of big data and AI for creating personalized health protocols, the trillion-dollar “longevity economy,” and...

Impetus Digital

Gamifying Remote Patient Monitoring

Dr. Emilia Molimpakis, CEO & Co-founder of Thymia, shares how their platform uses video games based on neuropsychology, alongside analyses of facial microexpressions and speech, to quickly, accurately, and objectively...

Impetus Digital

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for Dupixent

The trial involved patients with eosinophilic oesophagitis, an inflammatory disease that damages the oesophagus and makes eating and drinking painful

Social Health Prescription: Connecting People, Empowering Patients, & Improving Outcomes

Lynda Brown-Ganzert, Founder & CEO of Curatio, discusses the concept of social health prescription and the inspiration behind Curatio. She also explores questions such as how AI and “intelligent matchmaking” can be leveraged...

Impetus Digital

- PMLiVE

FDA accepts Priority Review for Dupixent in children with moderate-to-severe atopic dermatitis

If approved, Dupixent would be the first biologic treatment available in the US for children aged six months to five years with the skin condition

- PMLiVE

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD

The treatment is the first-of-its-kind for patients living with cold agglutinin disease, a rare blood disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links